We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Johnson & Johnson | LSE:0R34 | London | Ordinary Share | JOHNSON & JOHNSON ORD (CDI) |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
159.60 | 170.00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 85.16B | 35.15B | 14.6028 | 11.33 | 393.11B |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
18:59:27 | O | 1 | 165.42 | USD |
Date | Time | Source | Headline |
---|---|---|---|
20/8/2024 | 13:12 | ALNC | J&J to pay up to USD1.7 billion for heart failure device firm V-Wave |
17/7/2024 | 12:25 | ALNC | TOP NEWS: Johnson & Johnson touts "robust pipeline" as sales rise |
31/5/2024 | 14:30 | ALNC | Johnson & Johnson ties up acquisition of Shockwave Medical |
01/5/2024 | 14:17 | ALNC | TOP NEWS: J&J proposes USD6.48 billion settlement of cancer lawsuits |
16/4/2024 | 11:54 | ALNC | TOP NEWS: Johnson & Johnson upgrades guidance on swing to earnings |
05/4/2024 | 12:02 | ALNC | TOP NEWS: J&J swoops for Shockwave Medical in USD13.1 billion deal |
25/3/2024 | 18:28 | ALNC | IN BRIEF: J&J submits US premarket approval application for Varipulse |
18/3/2024 | 11:10 | ALNC | IN BRIEF: Johnson & Johnson receives FDA recommendation for Carvykti |
23/2/2024 | 18:32 | ALNC | IN BRIEF: Johnson & Johnson gets EMA nod for Carvykti in myeloma |
02/2/2024 | 06:22 | ALNC | TOP NEWS: US sends drugmakers initial offers in Medicare price talks |
Johnson & Johnson (0R34) Share Charts1 Year Johnson & Johnson Chart |
|
1 Month Johnson & Johnson Chart |
Intraday Johnson & Johnson Chart |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions